Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA; Monash University, Melbourne, Victoria, Australia.
Br J Anaesth. 2022 Sep;129(3):275-278. doi: 10.1016/j.bja.2022.06.016. Epub 2022 Aug 2.
Chiu and colleagues report a retrospective analysis describing the 5-yr trend in both intraoperative fluid and vasopressor administration in 32 250 patients undergoing elective abdominal surgery within the Multicenter Perioperative Outcomes Group (MPOG) database from 2015 to 2019, and exploring the association between these two factors and acute kidney injury. Modelling predicted the lowest risk for acute kidney injury when the administered crystalloid volume was 15-20 ml kg h, and an 80% increase in risk for acute kidney injury as intraoperative vasopressor use increased from 0 to 0.04 μg kg min of norepinephrine equivalents. Although these results are consistent with those of a large, randomised trial (REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery [RELIEF]) published in 2018, the mean intraoperative volume of crystalloid administered in the current study declined monotonically through every year included, from 6.4 ml kg h in 2015 to 5.5 ml kg h in 2019. These new findings support the broad generalisability of the RELIEF trial; highlight the complexity of the relationship between intravenous crystalloid volume infused, arterial pressure, and acute kidney injury; and demonstrate the ongoing challenge of translating high-quality evidence into clinical practice.
邱等报告了一项回顾性分析,描述了 2015 年至 2019 年期间,多中心围手术期结局组(MPOG)数据库中 32250 例择期腹部手术患者术中液体和血管加压素给药的 5 年趋势,并探讨了这两个因素与急性肾损伤之间的关系。模型预测,当给予的晶体量为 15-20ml/kg/h 时,急性肾损伤的风险最低,当术中血管加压素使用从 0 增加到 0.04μg/kg/min 去甲肾上腺素当量时,急性肾损伤的风险增加 80%。尽管这些结果与 2018 年发表的一项大型随机试验(限制与宽松液体治疗在主要腹部手术中的比较[RELIEF])一致,但本研究中术中给予的晶体量在每年都呈单调下降趋势,从 2015 年的 6.4ml/kg/h 下降到 2019 年的 5.5ml/kg/h。这些新发现支持 RELIEF 试验的广泛普遍性;强调了静脉内晶体量输注、动脉压和急性肾损伤之间关系的复杂性;并证明了将高质量证据转化为临床实践的持续挑战。